FDA approved enzalutamide (XTANDI Capsules, Medivation, Inc. and Astellas Pharma US, Inc.), for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. August 31, 2012. More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm317997.htm
| This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
